Is Compounded Semaglutide Available? Understanding the Recent Changes

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Compounded semaglutide is still dispensed by licensed 503A pharmacies, but the rules governing when it can be dispensed changed materially during 2025, and most of what is written about it online predates that change. The short chronology: semaglutide went onto the FDA drug shortage list, which opened a statutory pathway for compounding; the shortage resolved; FDA enforcement discretion ended on April 22 and May 22, 2025; and the market reverted to the older, narrower basis of compounding for an individual patient whose medical need cannot be met by an approved drug. Here is what that means in practice.

The Chronology, In Order

Demand for semaglutide outstripped supply, and the product appeared on the FDA drug shortage list. The FDA states that compounders may prepare compounded versions of a drug on FDA's drug shortages list if the compounded drug meets certain conditions detailed in federal law — that is the pathway that opened.

Tirzepatide's shortage resolved first. Enforcement discretion for compounded tirzepatide ended February 18 and March 19, 2025, the two dates reflecting different categories of compounder.

Semaglutide followed. Enforcement discretion for compounded semaglutide ended April 22 and May 22, 2025. From those dates, the shortage-based justification no longer applied.

What the Change Did and Did Not Do

It did not make compounding unlawful. Section 503A compounding for an individual patient remains a legitimate, long-established part of pharmacy practice with a statutory basis and state board oversight.

It did remove the broad justification that had supported high-volume compounding of a commercially available drug. The FDA's general position is that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.

The practical result is that the clinical rationale now has to be individual and documented, rather than resting on a shortage that no longer exists. That is a real change in how prescriptions are written and justified.

What Also Changed on the Approved Side

The approved landscape widened considerably during the same period, which changes the calculus. Wegovy tablets were approved December 22, 2025 at 1.5, 4, 9 and 25 mg. Wegovy HD, at 7.2 mg once weekly, was approved March 19, 2026 and is now the labeled maximum for Wegovy injection.

Foundayo (orforglipron) was approved April 1, 2026 as an oral small-molecule tablet for chronic weight management. The Wegovy presentation range also expanded in the 06/2026 label revision to include a single-patient-use FlexTouch pen delivering four 2.4 mg doses, alongside single-dose pens and syringes.

More approved options, including oral ones, changes what "cannot be treated with an FDA-approved medication" means for any individual patient — which is precisely the standard that now governs.

Enforcement Has Focused on the Fringe

The FDA has warned about fraudulent compounded semaglutide and tirzepatide carrying false label information, including labels naming pharmacies that did not compound the product and in some cases pharmacies that do not exist.

It has warned companies selling unapproved products labeled "for research purposes" or "not for human consumption" directly to consumers with dosing instructions, and has warned telehealth companies for marketing retatrutide, distributors for selling it to compounders, and outsourcing facilities for repackaging it.

It has established an import alert covering GLP-1 active pharmaceutical ingredients with potential quality concerns, structured as a green list that exempts compliant manufacturers and that the agency says does not create new limits on lawful compounding.

The Safety Reporting Since the Change

As of May 31, 2026 the FDA reported receiving 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide, while noting that state-licensed pharmacies which are not outsourcing facilities are not federally required to report, so these are likely undercounts.

Dosing error remains the distinctive signal — incorrect measurement and self-administration by patients, miscalculation by clinicians, and prescribing beyond the doses in the approved label, with some events requiring hospitalization.

Cold chain complaints continue as well. The agency recommends not using any injectable GLP-1 drug that arrives warm or with insufficient refrigeration, since these products require refrigeration as stated in their package inserts.

What to Do With This Information

If you are currently on a compounded preparation, ask your prescriber what clinical basis is documented, and ask which state-licensed pharmacy compounds it. Both are reasonable questions with straightforward answers in a legitimate arrangement.

If you are considering starting, understand that you are choosing a category that is not FDA-approved, whose trial evidence belongs to the approved products, and whose regulatory footing has moved once already.

Either way, build a continuity plan. Randomised withdrawal trials across the GLP-1 class consistently show substantial weight regain after discontinuation, so an unplanned interruption has the same effect as stopping deliberately.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide still available?

Yes, from licensed 503A compounding pharmacies, but on a patient-specific basis rather than the broad shortage-based allowance that applied earlier. FDA enforcement discretion for compounded semaglutide ended April 22 and May 22, 2025. Since then, the basis has been compounding for a patient whose medical need cannot be met by an FDA-approved drug, as documented by the prescriber.

What exactly changed in 2025?

Semaglutide and tirzepatide came off the FDA drug shortage list, which closed the statutory pathway allowing compounders to prepare versions of shortage drugs under specified conditions. Enforcement discretion ended February 18 and March 19, 2025 for tirzepatide and April 22 and May 22, 2025 for semaglutide, with the two dates reflecting different categories of compounder.

Did compounding become illegal?

No. Section 503A compounding for an individual patient remains a legitimate, long-established part of pharmacy practice with a statutory basis and state board of pharmacy oversight. What ended was the broad shortage-based justification. The FDA's general position is that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.

How does the wider approved landscape affect this?

It raises the bar for what counts as an unmet need. Wegovy tablets were approved December 22, 2025, Wegovy HD at 7.2 mg on March 19, 2026, and Foundayo (orforglipron) as an oral tablet on April 1, 2026. With more approved options including oral ones, the question of whether an approved product can meet a given patient's need has a different answer than it did in 2024.

What should I ask about my current prescription?

What clinical basis is documented for compounding rather than using an approved product, which state-licensed pharmacy compounds it, whether the base form rather than a salt form is used, and what potency and sterility testing is performed. Also confirm that a licensed clinician is reachable after delivery, which the FDA treats as a marker of a legitimate service.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.